Shield Therapeutics plc
Research Shield Therapeutics plc (STX.L) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerSTX.L
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyGBX
- Financial periodFY2025
- RevenueUSD 49.70M
- Revenue growth54.4%
- Net income-USD 17.66M
- Free cash flow-USD 3.68M
- Gross margin46.4%
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 49.70M | -USD 17.66M | -USD 3.68M | 46.4% | -0.02 | USD 11.62M | USD 30.14M | -USD 15.08M |
| FY2024 | USD 32.18M | -USD 27.18M | -USD 9.19M | 46.4% | -0.03 | USD 6.52M | USD 26.37M | -USD 1.32M |
| FY2023 | USD 13.09M | -USD 33.29M | -USD 40.07M | 30.8% | -0.05 | USD 13.95M | USD 20.25M | USD 15.03M |
| FY2022 | USD 5.50M | -USD 49.79M | -USD 24.88M | 44.7% | -0.21 | USD 3.40M | USD 7.35M | USD 6.54M |
| FY2021 | USD 2.05M | -USD 26.56M | -USD 27.43M | 35.5% | n/a | USD 16.35M | USD 210.00K | USD 55.35M |
About Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.
Related stock research
Other Healthcare stocks
Frequently asked questions
What does Shield Therapeutics plc do?
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.